Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.

Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, Wedzicha JA.

Eur Respir J. 2007 Sep;30(3):472-8. Epub 2007 May 15.

2.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
3.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators..

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

4.

The effect of tiotropium on exacerbations and airflow in patients with COPD.

Dusser D, Bravo ML, Iacono P.

Eur Respir J. 2006 Mar;27(3):547-55. Erratum in: Eur Respir J. 2006 May;27(5):1076.

5.

Inflammatory changes, recovery and recurrence at COPD exacerbation.

Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA.

Eur Respir J. 2007 Mar;29(3):527-34. Epub 2006 Nov 15.

6.

A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.

Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA.

COPD. 2012 Apr;9(2):111-20. doi: 10.3109/15412555.2011.641803.

PMID:
22458939
7.

Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.

Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC.

Eur Respir J. 2009 Apr;33(4):778-84. doi: 10.1183/09031936.00115308. Epub 2009 Jan 7.

8.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium..

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
9.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S.

Thorax. 2003 May;58(5):399-404. Erratum in: Thorax. 2005 Feb;60(2):105.

10.

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.

Rabe KF, Fabbri LM, Israel E, Kögler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF.

Lancet Respir Med. 2014 Jan;2(1):44-53. doi: 10.1016/S2213-2600(13)70248-0. Epub 2013 Dec 5.

PMID:
24461901
11.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S.

Ann Intern Med. 2005 Sep 6;143(5):317-26.

PMID:
16144890
12.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators..

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

13.

[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].

Beeh KM, Beier J, Buhl R, Stark-Lorenzen P, Gerken F, Metzdorf N; ATEM-Studiengruppe..

Pneumologie. 2006 Jun;60(6):341-6. German.

PMID:
16761228
14.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators..

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

15.

A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.

Anzueto A, Niewoehner DE, Leimer I, Rühmkorf F, Celli BR, Decramer M, Tashkin DP.

Respir Med. 2013 Dec;107(12):1912-22. doi: 10.1016/j.rmed.2013.07.020. Epub 2013 Aug 20.

16.

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group..

Eur Respir J. 2002 Feb;19(2):209-16.

17.
18.

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M.

Respir Med. 2010 Nov;104(11):1659-67. doi: 10.1016/j.rmed.2010.07.016. Epub 2010 Aug 17.

19.

Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations.

Halpin D, Menjoge S, Viel K.

Prim Care Respir J. 2009 Jun;18(2):106-13. doi: 10.4104/pcrj.2009.00017.

20.

Supplemental Content

Support Center